Shanghai Haohai Biological Technology Co. Ltd - Asset Resilience Ratio
Shanghai Haohai Biological Technology Co. Ltd (5HB) has an Asset Resilience Ratio of 1.13% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Haohai Biological Technology Co short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Shanghai Haohai Biological Technology Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Shanghai Haohai Biological Technology Co (5HB) total assets.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Haohai Biological Technology Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 5HB current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €76.11 Million | 1.13% |
| Total Liquid Assets | €76.11 Million | 1.13% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Haohai Biological Technology Co. Ltd maintains only 1.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Haohai Biological Technology Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Haohai Biological Technology Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Shanghai Haohai Biological Technology Co. Ltd (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Shanghai Haohai Biological Technology Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.13% | €76.11 Million ≈ $88.98 Million |
€6.72 Billion ≈ $7.86 Billion |
-0.10pp |
| 2024-12-31 | 1.23% | €87.85 Million ≈ $102.70 Million |
€7.12 Billion ≈ $8.33 Billion |
+1.08pp |
| 2023-12-31 | 0.16% | €11.08 Million ≈ $12.96 Million |
€7.11 Billion ≈ $8.31 Billion |
+0.06pp |
| 2022-12-31 | 0.10% | €6.75 Million ≈ $7.89 Million |
€6.89 Billion ≈ $8.06 Billion |
+0.01pp |
| 2021-12-31 | 0.09% | €6.38 Million ≈ $7.45 Million |
€6.95 Billion ≈ $8.13 Billion |
-0.15pp |
| 2020-12-31 | 0.24% | €15.14 Million ≈ $17.71 Million |
€6.30 Billion ≈ $7.36 Billion |
-1.59pp |
| 2018-12-31 | 1.83% | €81.28 Million ≈ $95.03 Million |
€4.44 Billion ≈ $5.19 Billion |
-- |
About Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and ot… Read more